Kaneka (4118) Q1 2025 earnings summary

Executive summary

• Net sales rose 8.6% year-over-year to ¥198.4 billion in Q1 FY2024, with operating income up 83.4% to ¥10.3 billion and net income attributable to owners up 65.8% to ¥7.0 billion.

• All business segments reported increased sales and profits, with especially strong growth in Material and Nutrition Solutions Units.

• The global economy showed moderate recovery but remained uncertain due to geopolitical risks and currency fluctuations.

Financial highlights

• Operating income margin improved to 5.2% from 3.1% year-over-year.

• Gross profit increased to ¥55,436 million from ¥46,386 million year-over-year.

• Ordinary income rose 52.0% year-over-year to ¥10,146 million.

• Net income per share increased to ¥110.38 from ¥65.35 year-over-year.

• Equity ratio stood at 51.9% as of June 30, 2024.

Outlook and guidance

• FY2024 full-year forecast maintained: net sales ¥790.0 billion (+3.6%), operating income ¥38.0 billion (+16.6%), net income attributable to owners ¥24.5 billion (+5.5%).

• Full-year net sales forecast is ¥790,000 million, up 5.5% year-over-year, with net income per share projected at ¥388.18.

• Expect continued earnings expansion in QoL SU and Material SU, with new product launches and margin improvements.

• Company-wide portfolio transformation to further improve profitability.

• No revisions to previously announced forecasts; company expects continued growth in Health Care and Nutrition segments, and improvement in Quality of Life and Material segments.